NCT00148876View on ClinicalTrials.gov

TBP Study With Capecitabine Plus Minus Trastuzumab

PHASE3CompletedINTERVENTIONAL
Enrollment

482

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Breast Cancer
Interventions
DRUG

Capecitabine

Capecitabine 2500 mg/m² orally day 1-14 q day 22

DRUG

Trastuzumab

Trastuzumab 6 mg/kg body weight every 3 weeks i.v.

Trial Locations (1)

60590

Johann Wolfgang Goethe Universität, Universitätsfrauenklinik, Frankfurt am Main

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

GBG Forschungs GmbH

OTHER

NCT00148876 - TBP Study With Capecitabine Plus Minus Trastuzumab | Biotech Hunter | Biotech Hunter